Clinical Trials
25 trialsNCT05150353 2026-06-04
AMYLOCARP
Ramsay Générale de Santé
Phase NA Completed
NCT07626476 2026-06-04
Autologous BCMA-targeted CAR-T Cell Injection for Relapsed/Refractory Light Chain Amyloidosis
Beijing Boren Hospital
Phase EARLY_PHASE1 Recruiting
NCT07624760 2026-06-03
MGUS-PET
University of Zurich
Phase NA Not yet recruiting
NCT05184088 2026-06-02
CArdiag
Lantheus Biosciences Ltd.
Phase 3 Completed
NCT07615270 2026-05-29
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
Stanford University
Phase EARLY_PHASE1 Not yet recruiting
NCT05839626 2026-05-27
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Phase 1 Terminated
NCT04847453 2026-05-13
Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT06963216 2026-05-11
A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis
Kedrion S.p.A.
Phase 3 Recruiting
NCT05145816 2026-05-07
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT05951049 2026-05-06
A Study of AT-02 in Subjects With Systemic Amyloidosis.
Attralus, Inc.
Phase 2 Active not recruiting
NCT06022939 2026-05-06
Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06769555 2026-04-29
BCMA/CD3 BiTE for RRAL or NDAL Amyloidosis With Insufficient Depth of Hematologic Response After Induction Therapy
Institute of Hematology & Blood Diseases Hospital, China
Phase NA Withdrawn
NCT07250269 2026-04-28
Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1 Recruiting
NCT07524634 2026-04-24
Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis
Case Comprehensive Cancer Center
Phase 2 Not yet recruiting
NCT06649695 2026-04-21
A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
European Myeloma Network B.V.
Phase 2 Recruiting
NCT04392960 2026-04-16
Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase NA Completed
NCT04512235 2026-04-07
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT05898646 2026-03-30
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
Mayo Clinic
Phase 2 Recruiting
NCT06971848 2026-03-30
ETCABIO
University Hospital, Angers
Phase NA Not yet recruiting
NCT07081646 2026-03-24
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
NCT04504825 2026-03-17
A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)
Alexion Pharmaceuticals, Inc.
Phase 3 Active not recruiting
NCT07224672 2026-03-17
ALANIS
GlaxoSmithKline
Phase 2 Not yet recruiting
NCT06192979 2026-03-09
Optimize First-line Treatment for AL Amyloidosis With t (11; 14)
Peking University People's Hospital
Phase NA Recruiting
NCT01758042 2026-03-06
BMT
Massachusetts General Hospital
Phase NA Completed
NCT06569147 2026-03-06
Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis
Brigham and Women's Hospital
Phase 1/2 Recruiting